Back to Search

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury

Tuscaloosa, Alabama, 35404
Scottsdale, Arizona, 85254
Seattle, Washington, 98108
Salem, Virginia, 24153
Richmond, Virginia, 23298
Search ended 09/28/2022

This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI).

Eligibility

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical

Ages Eligible for Study Min Age: 18 years - Max Age: 75 years
Sexes Eligible for Study Female
Accepts Healthy Volunteers Yes

Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
River Forest, Illinois and more
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
Herpes Zoster Read more
Tuscaloosa, Alabama and more
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Neurobehavioral Disinhibition Read more
Pelham, Alabama and more
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Cytomegalovirus Infection Read more